Introduction - A solution to select personalized treatments — Oncompass Medicine

Oncompass Medicine

Oncompass Medicine is a Hungarian medical enterprise dealing with the development of decision support and diagnostic medical devices that help the personalized treatment of cancer patients. 

Oncompass was the first to develop a medical device based on artificial intelligence that was proved to be successful in facilitating the therapeutic decision making process of the personalized treatment for cancer patients. For the effectiveness of the results Oncompass has developed a complex decision support system as well as a quality assured procedure. 

2021

The most promising technological enterprise in Europe; Oncompass Medicine has won the Future Unicorn Prize with the software the company developed for the selection of the targeted therapy of cancer patients.

2020

The oncology software system of Oncompass has won the Informatics Innovation Award of the Hungarian Association for Innovation in 2019.

2020

We presented at the ASCO (American Society of Clinical Oncology) conference the results of the clinical research conducted in cooperation with the Parisian Marie Curie Institute, that proofs that the medical software of Oncompass based on Artificial Intelligence does not only facilitate the work of the therapist, but as a new medical method, the digital therapy planning enhances the effectiveness of the treatment of cancer patients.

2020

For the sake of the local development of digital therapies, the Ministry of Innovation and Technology, the leading medical university of Hungary and Oncompass Medicine has signed a strategic contract for cooperation.

2020

According to the results presented at the congress of ESMO (European Society for Medical Oncology) the digital therapy planning conducted with the medical software of Oncompass Medicine can be routinely applied with children with cancer. In case of more than half of the children participating in the program the professionals indicated targeted treatments that would not have been considered without the molecular examination and digital therapy planning.

2019

On the 11th of October, the decision support software of Oncompass was awarded with the best abstract prize on the international conference, “Breakthrough Innovations in Oncology” of ASCO (American Society of Clinical Oncology) held in Bangkok, dealing with the application of artificial intelligence in oncology.

2019

Oncompass Medicine won the first place of GET IN THE RING V4! the innovation and start-up contest of the Visegrád Group.

2017

As of 2017, as a Hungarian medical-biotechnological enterprise, our consortium partners are the two leading oncology institutions in the National Innovation Oncogenic and Precision Oncology Program.

2016

The first version of Oncompass' informatics device for the evaluation of molecular diagnostic examinations and the selection of the effective therapy was introduced in 2016 at the world conference of personalized medical service at Silicon Valley.

2012

Dr. István Peták the founder and leader of Oncompass Medicine was awarded with Gábor Dénes prize what is given to the professionals who create outstanding intellectual works and transfer the new knowledge to practice.

2010

Our summary of the diagnostic examinations required for the application of the personalized therapies was published in Nature Reviews, a scientific journal.

2003

The medical researchers returning to Hungary from abroad founded Oncompass Medicine in 2003, with the creed of asserting the right of the patients to access the results of local and international biomedical researches.

2003

The researchers of Oncompass Medicine were among the firsts in Hungary to report the first successful targeted therapy possibility in case of lung cancer patients.

Asco Breakthrough

ASCO Breakthrough Innovations in Oncology

2019 Read more
More

About us

Our story

2003— —2024

Oncompass Medicine is a Hungarian medical enterprise dealing with the development of decision support and diagnostic medical devices that help the personalized treatment of cancer patients. 

More information